Throughout the recent activity, **Catalent (CTLT)** has been a focus with regards to its Q3 earnings, margins, and financial results. Despite reporting a Q3 loss below estimates, the company revealed positive gross margin and an optimistic 2024 revenue guidance. Both RBC Capital and Novo Holdings maintain outperform recommendations for the company. Notably, Novo Holdings have acquired the company in a $16.5B deal, a major development that boosted Catalent's stock by 10%. This acquisition also saw Novo Nordisk stepping up to meet the GLP-1 demand. Catalent recently made an important cooperation deal with Elliot Investment and indicated potential in pre-filled syringe production. Despite the bullish performance, some investors have unloaded their shares causing a minor dip in stock value. The company also faced a probe from FTC and shareholder lawsuit allegations. Yet, it showcased strength with a 9.8% increase in a single session, a positive fiscal Q3 snapshot, and being part of a multibillion-dollar production capacity deal.
Catalent CTLT News Analytics from Wed, 28 Jun 2023 07:00:00 GMT to Thu, 09 May 2024 17:31:00 GMT -
Rating -1
- Innovation 0
- Information 8
- Rumor 5
